C.R. Bard Inc. (BCR) Says FDA Approves 6-Month Primary End Point for Lutonix Below-the-Knee Drug Coated Balloon
Tweet Send to a Friend
C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
